News
Public · Published
Canaccord Genuity maintains Twist Bioscience at Buy, lowers price target to $150 from $205
Canaccord Genuity kept its Buy rating on Twist Bioscience but cut its price target to $150 from $205, a 26.8% reduction. The revised target implies 31.3% upside from the November 12 closing price of $114.22.
Published:
Updated:
What happened
Canaccord Genuity kept its Buy rating on Twist Bioscience but cut its price target to $150 from $205, a 26.8% reduction. The revised target implies 31.3% upside from the November 12 closing price of $114.22.
Confirmed
Global impact / market context
The lower target signals that Canaccord sees less potential value for Twist Bioscience than before, even while retaining its Buy rating. If other analysts or investors respond similarly, expectations for the company’s shares could weaken, potentially affecting how readily it can raise money through share sales.
Analyst inference
This is one analyst’s assessment, not a company announcement or a reported change in Twist Bioscience’s business. The article gives no reason for the target cut and no new operating or financial results, so it does not establish that revenue, costs, or cash available have changed.
Analyst inference
What to watch
- Watch for Canaccord’s stated reasons for the lower target; the article provides none, leaving investors unable to connect the change to specific business assumptions. Analyst inference
- Look for future analyst rating or target changes, which could show whether this lower valuation view is isolated or shared by other research firms. Analyst inference
- Compare later company disclosures on revenue, costs, and cash available with the assumptions behind analyst targets; the supplied article reports no such business updates. Analyst inference
Evidence
- Original source link unavailable